Terms: = Uterine cancer AND BLM, MGC131620, 641, ENSG00000197299, MGC131618, RECQ2, RECQL2, RECQL3, MGC126616, BS AND Prognosis
5 results:
1. Competitive Risk Model Nomogram to Predict prognosis in Patients Aged Over 65 Years with nonmetastatic Cervical cancer: A SEER Population-Based Study.
Jiao S; Guo L; Da F; Gao Q; Ren Z; Wang J; Fu Q; Liu J
Technol Cancer Res Treat; 2023; 22():15330338231164191. PubMed ID: 37078156
[No Abstract] [Full Text] [Related]
2. A novel prognostic nomogram utilizing the 2018 FIGO staging system for cervical cancer: A large multicenter study.
Tang X; Guo C; Liu S; Guo J; Hua K; Qiu J
Int J Gynaecol Obstet; 2021 Oct; 155(1):86-94. PubMed ID: 33587753
[TBL] [Abstract] [Full Text] [Related]
3. Risk of Gynecologic cancer as Second versus First Primary cancer in Japan.
Ogawa C; Nakamura K; Matsuoka H; Matsubara Y; Haraga J; Masuyama H
Acta Med Okayama; 2020 Apr; 74(2):109-114. PubMed ID: 32341584
[TBL] [Abstract] [Full Text] [Related]
4. Unexpected uterine sarcomas in 4478 patients with electric power morcellation for leiomyomas.
Chen Q; Shi H; Lu W; Lu B
Eur J Obstet Gynecol Reprod Biol; 2018 Nov; 230():85-89. PubMed ID: 30245442
[TBL] [Abstract] [Full Text] [Related]
5. Response rate and cell-cycle changes due to intra-arterial infusion chemotherapy with cisplatin and bleomycin for locally recurrent uterine cervical cancer.
Kigawa J; Kanamori Y; Ishihara H; Minagawa Y; Iwamoto K; Terakawa N
Am J Clin Oncol; 1992 Dec; 15(6):474-9. PubMed ID: 1280402
[TBL] [Abstract] [Full Text] [Related]